<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS136060</article-id>
<article-id pub-id-type="doi">10.1101/2021.09.30.462420</article-id>
<article-id pub-id-type="archive">PPR402764</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>SARS-CoV-2 Beta variant infection elicits potent lineage-specific and cross-reactive antibodies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Reincke</surname>
<given-names>S Momsen</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="fn" rid="FN1">*</xref>
<xref ref-type="corresp" rid="CR1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Meng</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="fn" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kornau</surname>
<given-names>Hans-Christian</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A5">5</xref>
<xref ref-type="fn" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Corman</surname>
<given-names>Victor M</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
<xref ref-type="aff" rid="A7">7</xref>
<xref ref-type="fn" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hoof</surname>
<given-names>Scott van</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sánchez-Sendin</surname>
<given-names>Elisa</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ramberger</surname>
<given-names>Melanie</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Wenli</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hua</surname>
<given-names>Yuanzi</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tien</surname>
<given-names>Henry</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schmidt</surname>
<given-names>Marie Luisa</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schwarz</surname>
<given-names>Tatjana</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jeworowski</surname>
<given-names>Lara Maria</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brandl</surname>
<given-names>Sarah E</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rasmussen</surname>
<given-names>Helle Foverskov</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Homeyer</surname>
<given-names>Marie A</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stöffler</surname>
<given-names>Laura</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Barner</surname>
<given-names>Martin</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kunkel</surname>
<given-names>Désirée</given-names>
</name>
<xref ref-type="aff" rid="A8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huo</surname>
<given-names>Shufan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Horler</surname>
<given-names>Johannes</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>von Wardenburg</surname>
<given-names>Niels</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kroidl</surname>
<given-names>Inge</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Eser</surname>
<given-names>Tabea M</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wieser</surname>
<given-names>Andreas</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Geldmacher</surname>
<given-names>Christof</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hoelscher</surname>
<given-names>Michael</given-names>
</name>
<xref ref-type="aff" rid="A9">9</xref>
<xref ref-type="aff" rid="A10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gänzer</surname>
<given-names>Hannes</given-names>
</name>
<xref ref-type="aff" rid="A11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Weiss</surname>
<given-names>Günter</given-names>
</name>
<xref ref-type="aff" rid="A12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schmitz</surname>
<given-names>Dietmar</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Drosten</surname>
<given-names>Christian</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prüss</surname>
<given-names>Harald</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="fn" rid="FN2">§</xref>
<xref ref-type="corresp" rid="CR1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wilson</surname>
<given-names>Ian A.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A13">13</xref>
<xref ref-type="fn" rid="FN2">§</xref>
<xref ref-type="corresp" rid="CR1">†</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kreye</surname>
<given-names>Jakob</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A14">14</xref>
<xref ref-type="fn" rid="FN2">§</xref>
<xref ref-type="corresp" rid="CR1">†</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Neurology and Experimental Neurology, Berlin, Germany</aff>
<aff id="A2">
<label>2</label>German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany</aff>
<aff id="A3">
<label>3</label>Helmholtz Innovation Lab BaoBab (Brain antibody-omics and B-cell Lab), Berlin, Germany</aff>
<aff id="A4">
<label>4</label>Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA</aff>
<aff id="A5">
<label>5</label>Neuroscience Research Center (NWFZ), Cluster NeuroCure, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany</aff>
<aff id="A6">
<label>6</label>Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Virology, Berlin, Germany and German Centre for Infection Research (DZIF), Berlin, Germany</aff>
<aff id="A7">
<label>7</label>Labor Berlin – Charité Vivantes GmbH, Berlin</aff>
<aff id="A8">
<label>8</label>Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Flow &amp; Mass Cytometry Core Facility, Berlin, Germany</aff>
<aff id="A9">
<label>9</label>Division of Infectious Diseases and Tropical Medicine, Medical Center of the University of Munich (LMU), Germany</aff>
<aff id="A10">
<label>10</label>German Center for Infection Research (DZIF), partner site Munich, Germany</aff>
<aff id="A11">
<label>11</label>Department of Internal Medicine, BKH Schwaz, Schwaz, Austria</aff>
<aff id="A12">
<label>12</label>Department of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria</aff>
<aff id="A13">
<label>13</label>The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA</aff>
<aff id="A14">
<label>14</label>Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Pediatric Neurology, Berlin, Germany</aff>
<author-notes>
<fn fn-type="equal" id="FN1">
<label>*</label>
<p id="P1">These authors contributed equally to this work.</p>
</fn>
<fn fn-type="equal" id="FN2">
<label>§</label>
<p id="P2">These authors contributed equally to this work.</p>
</fn>
<corresp id="CR1">
<label>†</label>Corresponding authors: <email>momsen.reincke@charite.de</email> (S.M.R.); <email>harald.pruess@charite.de</email> (H.P.); <email>wilson@scripps.edu</email> (I.A.W.); <email>jakob.kreye@charite.de</email> (J.K.)</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>06</day>
<month>10</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>30</day>
<month>09</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
<license>
<ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref>
<license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p>
</license>
</permissions>
<abstract>
<p id="P3">SARS-CoV-2 Beta variant of concern (VOC) resists neutralization by major classes of antibodies from non-VOC COVID-19 patients and vaccinated individuals. Here, serum of Beta variant infected patients revealed reduced cross-neutralization of non-VOC virus. From these patients, we isolated Beta-specific and cross-reactive receptor-binding domain (RBD) antibodies. The Beta-specificity results from recruitment of novel VOC-specific clonotypes and accommodation of VOC-defining amino acids into a major non-VOC antibody class that is normally sensitive to these mutations. The Beta-elicited cross-reactive antibodies share genetic and structural features with non-VOC-elicited antibodies, including a public VH1-58 clonotype targeting the RBD ridge independent of VOC mutations. These findings advance our understanding of the antibody response to SARS-CoV-2 shaped by antigenic drift with implications for design of next-generation vaccines and therapeutics.</p>
</abstract>
</article-meta>
</front>
<body>
<p id="P4">In the course of the COVID-19 pandemic, multiple SARS-CoV-2 lineages have emerged including lineages defined as variants of concern (VOC), such as Alpha (also known as lineage B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2). VOCs are associated with increased transmissibility, virulence and/or resistance to neutralization by sera from vaccinated individuals and convalescent COVID-19 patients who were infected with the original, non-VOC strain (<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R7">7</xref>). These distinct lineages carry a variety of mutations in the spike protein, several of which are within the receptor binding domain (RBD), especially at residues K417, L452, T478, E484, and N501. Some mutations like N501Y are associated with enhanced binding to angiotensin-converting enzyme 2 (ACE2), largely driving the global spread of VOCs incorpororating these mutations (<xref ref-type="bibr" rid="R2">2</xref>). However, with increasing immunity either through natural infection or vaccination, antibody escape might become more relevant in emerging VOCs. Many studies have investigated RBD antibodies in COVID-19 patients prior to identification of SARS-CoV-2 variants, and we refer to these as non-VOC antibodies. Non-VOC RBD antibodies revealed a preferential response towards distinct epitopes with enriched recruitment of particular antibody germline genes, where the most prominent were VH3-53 and closely related VH3-66, as well as VH1-2 (<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R9">9</xref>). Structural and functional classification of non-VOC RBD mAbs has demonstrated that mAbs from these three enriched germline genes form two major classes of receptor-binding site (RBS) mAbs whose binding and neutralizing activity depends on either K417 and/or E484 (<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R10">10</xref>). Mutations at these key residues (K417N and E484K) and at N501Y are hallmarks of the Beta variant (<xref ref-type="bibr" rid="R2">2</xref>), and largely account for the reduced neutralizing activity of sera from vaccinated individuals and convalescent COVID-19 patients against this VOC (<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R12">12</xref>). These key mutations also occur in further sublineages including an Alpha variant strain carrying E484K and a Delta variant strain carrying K417N (Delta Plus). Of all current VOCs, the Beta variant appears to be most resistant to neutralization from non-VOC sera, suggesting conspicuous differences in its antigenicity (<xref ref-type="bibr" rid="R13">13</xref>). However, little is known about the antibody response elicited by Beta variant infection. For example, it is unknown if antibodies targeting the RBD of the Beta variant (RBD Beta) share the preferential recruitment of particular germline genes with non-VOC antibodies, and whether VOC-defining mutations K417N and E484K could be accommodated in the canonical binding modes of public antibody classes like VH3-s53/VH3-66 antibodies. Investigating Beta variant induced immunity can therefore bolster efforts to monitor and prevent the spread of SARS-CoV-2 by informing vaccine design in the context of the ongoing antigenic drift. Thus, we set out to explore genetic, functional and structural features of the antibody response against RBD Beta compared to non-VOC RBD.</p>
<p id="P5">We identified 40 individuals infected with the SARS-CoV-2 Beta variant from three metropolitan areas in Germany and Austria (<xref ref-type="supplementary-material" rid="SD1">table S1</xref>). Serum from these patients was collected 38.6 ± 19.2 days after their first positive SARS-CoV-2 RT-PCR test. The patients’ IgG bound to non-VOC nucleocapsid protein and/or non-VOC spike protein in 37 of 40 patients with stronger reactivity to RBD Beta than to non-VOC RBD (<xref ref-type="supplementary-material" rid="SD1">fig. S1A</xref>). The VOC patients’ sera also inhibited ACE2 binding to RBD Beta to a greater extent than to non-VOC RBD (<xref ref-type="supplementary-material" rid="SD1">fig. S1B, table S1</xref>), indicating the presence of highly effective RBD antibodies after Beta variant infection. Reactivity to non-VOC spike S1 antigen was confirmed in an additional commercially available ELISA; however, only 23 of 40 samples tested positive according to the manufacturer’s cutoff (<xref ref-type="supplementary-material" rid="SD1">fig. S1, C and D</xref>). In a plaque reduction neutralization test (PRNT), 37 of 40 sera neutralized an authentic SARS-CoV-2 Beta isolate (B.1.351) with a half-maximal inhibitory concentration (IC<sub>50</sub>) at 1:20 dilution or greater (<xref ref-type="fig" rid="F1">Fig. 1A</xref>). On the other hand, only 11 of 40 sera neutralized non-VOC authentic virus of Munich isolate 984 (<xref ref-type="bibr" rid="R14">14</xref>) with an IC<sub>50</sub> at 1:20 dilution or greater (<xref ref-type="fig" rid="F1">Fig. 1B</xref>). The neutralizing activity against the two viral isolates was modestly correlated (<xref ref-type="supplementary-material" rid="SD1">fig. S1E</xref>), with a ~20.4-fold reduction of neutralizing activity against the non-VOC virus compared to Beta as measured by the area under the curve (AUC) of neutralization titers (<xref ref-type="fig" rid="F1">Fig. 1C</xref>), indicating limited breadth of serum antibodies in our cohort. A converse effect has been reported after immune responses against non-VOC RBD in cohorts of convalescent patients and of vaccinated individuals (<xref ref-type="bibr" rid="R2">2</xref>), where neutralization of SARS-CoV-2 Beta was ~8 to ~14 fold reduced compared to non-VOC virus (<xref ref-type="bibr" rid="R1">1</xref>–<xref ref-type="bibr" rid="R6">6</xref>). No positive correlation was found between neutralizing antibodies against Beta and the timepoint of sample collection relative to first positive PCR test (<xref ref-type="supplementary-material" rid="SD1">fig. S1F</xref>). Neutralizing antibodies against Beta modestly correlated with age (<xref ref-type="supplementary-material" rid="SD1">fig. S1G</xref>), but no statistically significant gender difference was observed (<xref ref-type="supplementary-material" rid="SD1">fig. S1H</xref>). Collectively, these data show that sera from Beta-infected patients exhibit reduced cross-reactivity and cross-neutralization to non-VOC SARS-CoV-2, impacting diagnostic antibody testing and assessment of antibody levels when using non-VOC antigens.</p>
<p id="P6">To investigate this difference in reactivity between RBD Beta and non-VOC RBD on the level of mAbs elicited by SARS-CoV-2 Beta variant infection, we isolated CD19<sup>+</sup>CD27<sup>+</sup> memory B cells from the peripheral blood of 12 donors in our cohort via fluorescence activated cell sorting using a recombinant RBD Beta (K417N/E484K/N501Y) probe (<xref ref-type="supplementary-material" rid="SD1">fig. S2A</xref>). Frequencies of RBD-double-positive memory B cells ranged from 0.007% to 0.1% (<xref ref-type="supplementary-material" rid="SD1">fig. S2B</xref>). Using single-cell Ig gene sequencing (<xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R16">16</xref>), we derived 289 pairs of functional heavy (IGH) and light (IGL) chain sequences from IgG mAbs (<xref ref-type="supplementary-material" rid="SD1">table S2</xref>). Sequence analysis showed enrichment of certain VH genes compared to mAbs derived from healthy, non-infected individuals, including VH1-58, VH3-30, VH4-39 and VH3-53, illustrating a preferential recruitment of certain VH genes (<xref ref-type="fig" rid="F2">Fig. 2A</xref>) and VH-JH gene combinations (<xref ref-type="supplementary-material" rid="SD1">fig. S3A</xref>). For some genes like VH1-58 and VH3-53, enrichment has previously been identified in CoV-AbDab, a database of published non-VOC SARS-CoV-2 mAbs (<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R17">17</xref>). We here confirmed this finding for all human RBD mAbs in this database (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). Consistent with previous reports from non-VOC SARS-CoV-2 infections (<xref ref-type="bibr" rid="R18">18</xref>–<xref ref-type="bibr" rid="R20">20</xref>), the number of somatic hypermutations (SHM) in the IGH and IGL chains was generally low in mAbs derived from our cohort (<xref ref-type="supplementary-material" rid="SD1">fig. S3B</xref>). Together, these findings argue for conservation of certain antibody sequence features between antibody responses in different donors and between antibody responses elicited against SARS-CoV-2 Beta variant and non-VOC viruses. Hence, we compared antibody sequences after Beta infection to all previously published non-VOC RBD antibodies and identified several clonotypes shared between both datasets (<xref ref-type="fig" rid="F2">Fig. 2B</xref>), some of which were present in multiple patients of our study (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). Taken together, these results demonstrate that a subset of the antibodies to RBD Beta and non-VOC RBD converge on recruitment of specific germline genes.</p>
<p id="P7">However, other gene enrichments found in our study like VH4-39 have not been identified within the CoV-AbDab mAbs (<xref ref-type="bibr" rid="R9">9</xref>) (<xref ref-type="fig" rid="F2">Fig. 2A</xref>), exemplifying concurrent divergence in the antibody response to the different RBDs. Strikingly, VH1-2, one of the most common genes contributing to the RBD antibody response to non-VOC SARS-CoV-2, was virtually absent in our dataset of Beta variant elicited mAbs (<xref ref-type="fig" rid="F2">Fig. 2A</xref> and <xref ref-type="supplementary-material" rid="SD1">table S2</xref>), in line with our previous predictions about the effect of Beta variant mutations on VH1-2 binding and neutralization (<xref ref-type="bibr" rid="R9">9</xref>). VH3-53/VH3-66 antibodies have previously been shown to bind to non-VOC RBD in two canonical binding modes, which involve residues K417 and E484, respectively; binding and neutralization of these antibodies are strongly affected by the K417N and E484K mutations in RBD Beta (<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R21">21</xref>). We therefore hypothesized a similarly reduced recruitment of VH3-53/VH3-66 mAbs after Beta variant infection. Surprisingly, we identified 15 VH3-53/VH3-66 mAbs, albeit at a reduced frequency compared to the CoV-AbDab dataset (4.7% vs. 19.4%), but still at an increased frequency compared to healthy donors (<xref ref-type="fig" rid="F2">Fig. 2A</xref>), thus indicating either a non-canonical binding mode or accommodation of these mutations into the known binding modes.</p>
<p id="P8">To determine the binding properties of antibodies elicited by SARS-CoV-2 Beta, we selected mAbs for expression and further characterization based on the following criteria: (i) mAbs that are clonally expanded within one patient, (ii) mAbs of clonotypes present in several patients in our dataset to decipher the shared antibody response to RBD Beta, (iii) mAbs of clonotypes found both in our and CoV-AbDab datasets to potentially identify cross-reactive mAbs, (iv) VH3-53/VH3-66 mAbs to elucidate the unexpected recurrent shared antibody response against RBD Beta, (v) mAbs of VH genes with strongest enrichment in our dataset, including VH4-39 and VH1-58. We identified 81 mAbs with strong binding to RBD Beta (<xref ref-type="supplementary-material" rid="SD1">table S3</xref>), as defined by detectable binding at 10 ng/ml. Of those, a majority (44 in total) revealed comparable binding to non-VOC RBD and were considered cross-reactive mAbs, whereas 37 mAbs did not bind non-VOC RBD at 10 ng/ml and were considered RBD Beta-specific.</p>
<p id="P9">We aimed to determine the residues that define the mAb binding selectivity for the 37 RBD Beta-specific mAbs, and performed ELISAs with single mutant constructs of RBD Beta and non-VOC RBD. For all three Beta-defining RBD mutations (K417N, E484K and N501Y), we identified mAbs with RBD binding that were dependent on a single residue, with a larger fraction of binders that were dependent on K484 (<xref ref-type="bibr" rid="R12">12</xref>) and Y501 (<xref ref-type="bibr" rid="R11">11</xref>) than N417 (<xref ref-type="bibr" rid="R3">3</xref>). The RBD Beta specificity of other mAbs was dependent on multiple residues (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). 26 of the RBD Beta-specific mAbs (70.2%) neutralized the authentic SARS-CoV-2 Beta isolate, with representation in all of the above-mentioned specificity categories (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). RBD Beta-specific mAbs were encoded by a broad variety of VH genes (<xref ref-type="fig" rid="F3">Fig. 3A</xref> and <xref ref-type="supplementary-material" rid="SD1">table S2</xref>). Interestingly, all nine VH4-39 mAbs with RBD Beta specificity from three different patients were Y501-dependent, comprising 81.8% of the mAbs in this category. This finding suggests a common binding mode of these mAbs that depends on Y501, a mutation that is present in RBD Beta, Alpha and Gamma, but not Delta, and may explain the frequent use of VH4-39 in mAbs to RBD Beta (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). VH4-39 Y501-dependent mAbs revealed few SHM in VH genes but no uniform pattern in other sequence features (<xref ref-type="supplementary-material" rid="SD1">fig. S4A</xref>). Although all VH4-39 RBD Beta-specific mAbs bind to a Y501-dependent epitope, their neutralization activity against authentic Beta virus showed noticeable differences (IC<sub>50</sub> ranging from 5.2 to 947 ng/ml, <xref ref-type="supplementary-material" rid="SD1">fig. S4B</xref>). Surface plasmon resonance measurements of these mAbs to RBD Beta revealed equilibrium dissociation constants (K<sub>D</sub>) between 3.39 and 80.4 nM (<xref ref-type="supplementary-material" rid="SD1">fig. S5A</xref>) with correlation to their PRNT-derived IC<sub>50</sub> values (<xref ref-type="supplementary-material" rid="SD1">fig. S5B</xref>), thereby providing an explanation for the variability in neutralizing activity within the VH4-39 Y501-dependent mAbs.</p>
<p id="P10">Furthermore, we identified three VH3-53/VH3-66 mAbs with RBD Beta specificity that all showed neutralizing activity. To determine whether this RBD Beta specificity results from a non-canonical binding mode or accommodation of the Beta variant-defining mutations in one of the two main VH3-53/VH3-66 mAb binding modes, we determined a crystal structure of VH3-53 antibody CS23 in complex with RBD Beta. Previously, we and others found that VH3-53/VH3-66 mAbs with short CDRs H3 (&lt;15 amino acids) target the RBS of non-VOC RBD via a canonical mode (<xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R22">22</xref>–<xref ref-type="bibr" rid="R25">25</xref>) that is highly sensitive to the K417N mutation (<xref ref-type="bibr" rid="R9">9</xref>). CS23 contains a short CDR H3 with only ten amino acids and is specific to N417 RBDs including RBD Beta (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). Perhaps unexpectedly, CS23 binds to RBD Beta in the canonical mode, with a nearly identical approach angle compared to non-VOC VH3-53 antibody CC12.3 (<xref ref-type="bibr" rid="R24">24</xref>) (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). We also previously determined that the CDR H1 <sup>33</sup>NY<sup>34</sup> and H2 <sup>53</sup>SGGS<sup>56</sup> motifs of VH3-53/VH3-66 mAbs are critical for RBD recognition (<xref ref-type="bibr" rid="R24">24</xref>). Here we find that CS23 retains these motifs and they interact with the RBD in the same way (<xref ref-type="fig" rid="F3">Fig. 3, C and D</xref>). Residues in CDR H3 usually interact with K417 and thus confer specificity to the non-VOC RBD (<xref ref-type="bibr" rid="R9">9</xref>). For example, V<sub>H</sub> D97 of CC12.1 forms a salt bridge with the outward facing RBD-K417, whereas V<sub>H</sub> F99 and V<sub>H</sub> G97 of CC12.3 interact with K417 through cation-π and hydrogen bonds (H-bonds), respectively (<xref ref-type="fig" rid="F3">Fig. 3, E and F</xref>). Instead, in RBD Beta, the shorter N417 flips inward and H-bonds with RBD-E406 and Q409 (<xref ref-type="fig" rid="F4">Fig. 4G</xref>). V<sub>H</sub> M98 occupies the vacated space and interacts with RBD-Y453, L455, and V<sub>L</sub> W91 in a hydrophobic pocket. We modeled in K417 and found that it would be unfavorable for RBD binding to CS23, as V<sub>H</sub> M98 now occupies the pocket that K417 normally accesses. CDR H3 contains a V<sub>H</sub> <sup>96</sup>TAMA<sup>99</sup> sequence that forms an ST motif that stabilizes CDR H3 and the disposition of M98. The first serine (S) or threonine (T) residue in a four of five residue ST motif makes two internal H-bonds from the side-chain oxygen of residue i to the main-chain NH of residue i + 2 or i + 3, and between the main-chain oxygen of residue i and the main-chain NH of residue i + 3 or i + 4. In this case, the T96 side chain H-bonds with the main-chain NH of M98, and the T96 main-chain oxygen H-bonds with the main-chain NH of A99 (<xref ref-type="supplementary-material" rid="SD1">fig. S6A</xref>). In fact, this V<sub>H</sub> <sup>96</sup>TxMx<sup>99</sup> motif is unique in all CDRs H3 of anti-RBD VH3-53/VH3-66 antibodies (<xref ref-type="bibr" rid="R17">17</xref>) and explains the newly acquired specificity of this VH3-53 antibody for an RBD with N417. Previously, non-VOC VH3-53 antibody COVOX-222 was shown to cross-react with RBD Beta but still bind the RBD in the canonical mode; in this case, a rare SHM V<sub>L</sub> S30P mutation accommodated Y501 (<xref ref-type="bibr" rid="R1">1</xref>) (<xref ref-type="supplementary-material" rid="SD1">fig. S6, B and C</xref>). Likewise, for CS23, the CDR L1 <sup>30</sup>SK<sup>31</sup> dipeptide is mutated to <sup>30</sup>GQ<sup>31</sup> and accommodates Y501 in the Beta variant (<xref ref-type="supplementary-material" rid="SD1">fig. S6D</xref>). Interestingly, another VH3-53 antibody of our cohort, CS82 is highly cross-reactive and resistant to all tested VOCs, including those with mutations at residues 417 and 484 (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). Moreover, CS82 also binds SARS-CoV (<xref ref-type="fig" rid="F4">Fig. 4A</xref>), which is unprecedented for any previous VH3-53 antibodies. CS82 competes with CR3022 (<xref ref-type="supplementary-material" rid="SD1">fig. S6E</xref>), suggesting a possible alternative binding interaction compared to the two binding modes of non-VOC VH3-53 antibodies that are sensitive to K417N and E484K, respectively (<xref ref-type="bibr" rid="R23">23</xref>, <xref ref-type="bibr" rid="R24">24</xref>). Collectively, VH3-53/VH3-66 mAbs contribute to the immune response to RBD Beta with mAbs that accommodate Beta-specific mutations into canonical modes and by mAbs that may bind in alternative binding modes.</p>
<p id="P11">We next aimed to characterize the functional breadth of the cross-reactive mAbs. 20 of the 44 cross-reactive mAbs (45.5%) neutralized authentic SARS-CoV-2 Beta isolate (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). To investigate their cross-reactivity against further RBD variants, we performed ELISAs with RBD constructs of all VOCs and also SARS-CoV. Whereas only two mAbs (10%) strongly detected SARS-CoV RBD, the majority of cross-reactive antibodies bound the RBD of Alpha, Gamma and Delta (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). In PRNT assays with further authentic virus isolates, 15 (75%) Beta variant neutralizing cross-reactive mAbs also neutralized non-VOC virus and 14 (70%) neutralized a Delta virus isolate (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). Thus, cross-reactive mAbs elicited from SARS-CoV-2 Beta infections revealed breadth in binding and neutralization of current VOCs. Six cross-neutralizing antibodies were encoded by VH1-58 (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). VH1-58 is the most enriched germline VH gene in RBD antibodies in both Beta variant and non-VOC infection (<xref ref-type="bibr" rid="R26">26</xref>) (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). In the context of RBD antibodies, VH1-58 almost exclusively pairs with JH3 (<xref ref-type="supplementary-material" rid="SD1">fig. S3A</xref>). The VH1-58/JH3/VK3-20/JK1 clonotype has been described in non-VOC infected individuals (<xref ref-type="bibr" rid="R20">20</xref>, <xref ref-type="bibr" rid="R26">26</xref>) and found in several patients within our cohort (<xref ref-type="fig" rid="F2">Fig. 2C</xref> and <xref ref-type="fig" rid="F4">Fig. 4B</xref>), thereby representing 2.4% of all IgG mAbs analyzed in this study (<xref ref-type="supplementary-material" rid="SD1">table S2</xref>). To elucidate the structural basis of this public pan-VOC clonotype, we determined crystal structures of CS44 and CV07-287, a mAb of the same clonotype that was isolated from a non-VOC infected individual (<xref ref-type="bibr" rid="R19">19</xref>), in complex with RBD Beta and non-VOC RBD respectively (<xref ref-type="fig" rid="F4">Fig. 4C</xref>). We compared the structures of CS44 and CV07-287 with other published VH1-58 antibodies, including COVOX-253 (<xref ref-type="bibr" rid="R27">27</xref>), S2E12 (<xref ref-type="bibr" rid="R28">28</xref>), A23-58.1, and B1-182.1 (<xref ref-type="bibr" rid="R26">26</xref>). These antibodies all target the RBD in the same binding mode (<xref ref-type="fig" rid="F4">Fig. 4C</xref>), which suggests that this public clonotype is structurally conserved. The dominant interaction of VH1-58 antibodies is with the RBD ridge region (residues 471–491), which accounts for ~75% of the entire epitope surface. Most of the VOC mutations occur outside of the ridge region (e.g. residues 417, 452, and 501) and are distant from the binding sites of VH1-58 antibodies CV07-287 and CS44 (<xref ref-type="fig" rid="F4">Fig. 4, E and F</xref>). Among the VOC-related residues, only T478 interacts with VH1-58 antibodies, but mutation to a lysine can be accommodated (<xref ref-type="fig" rid="F4">Fig. 4A</xref>) (<xref ref-type="bibr" rid="R26">26</xref>). V<sub>H</sub> W50 and Y52 in CDR H2 provide hydrophobic interactions with the RBD (<xref ref-type="fig" rid="F4">Fig. 4, G and I</xref>). CDR H3 also forms extensive interactions with the RBD. The CDR H3 sequences of 38 antibodies that belong to this clonotype (<xref ref-type="bibr" rid="R17">17</xref>) (<xref ref-type="fig" rid="F4">Fig. 4D</xref>) are highly conserved, and all contain a disulfide bond between V<sub>H</sub> C97 and C100b, with four relatively small residues (G, S, T) in-between (<xref ref-type="fig" rid="F4">Fig. 4, D, H and J</xref>). V<sub>H</sub> D100d is also conserved (<xref ref-type="fig" rid="F4">Fig. 4D</xref>), forming H-bonds with S477 and T478 (<xref ref-type="fig" rid="F4">Fig. 4, H and J</xref>). In addition, the conserved V<sub>H</sub> P95 and F100f (<xref ref-type="fig" rid="F4">Fig. 4D</xref>) stack with RBD-F486 together with V<sub>H</sub> W50, V<sub>L</sub> Y91, and V<sub>L</sub> W96 (<xref ref-type="fig" rid="F4">Fig. 4, H and J</xref>). While E484 is often an important residue for antibody binding on the ridge region, here it is 5 Å distant from the antibodies and mutations at this site have not been reported as being sensitive for VH1-58 antibodies.</p>
<p id="P12">Thousands of anti-SARS-CoV-2 mAbs were isolated before the VOCs started to emerge (<xref ref-type="bibr" rid="R17">17</xref>), many of which are highly potent but sensitive or resistant to VOCs. Here, we characterized the antibody response to the RBD after SARS-CoV-2 Beta variant infection to provide insights into diverging and converging features of antibodies elicited by this lineage compared to non-VOC-elicited antibodies. Our analysis of polyclonal patient sera indicates that non-VOC RBD based diagnostics may underestimate antibody titers after Beta variant infection or even result in a false-negative serological assessment of a prior infection. This issue could be addressed by the use of VOC-based antigens, but these data challenge the concept of defining a universal threshold for protective antibody titers or threshold-based reasoning for booster vaccination.</p>
<p id="P13">Furthermore, on the monoclonal level, we show that RBD mAbs with Beta-specificity are frequent after Beta infection, similar to the frequency of RBD mAbs that do not react with RBD Beta after non-VOC infection or vaccination (<xref ref-type="bibr" rid="R2">2</xref>). Antibodies with Beta-specificity include novel VOC-specific public clonotypes such as Y501-dependent VH4-39 mAbs, and others in the major non-VOC antibody class encoded by VH3-53/VH3-66 genes. Surprisingly, VOC-defining mutations in the Beta variant can be accommodated by local conformational changes and mutations in these VH3-53/VH3-66 mAbs that enable canonical mode binding. Moreover, a subset of RBD Beta elicited mAbs was cross-reactive to non-VOC RBD and also against the other VOCs investigated including the Delta variant, with multiple of these mAbs revealing potent cross-neutralization. VH1-58 antibodies form a clonotype with both ultra-high potency and high resistance to currently circulating VOCs, including variants of concern Alpha, Beta, Gamma and Delta (<xref ref-type="bibr" rid="R26">26</xref>). Here, we show that pan-VOC VH1-58 antibodies are also frequently elicited by the Beta variant, and target the S protein in a nearly identical binding mode compared to those isolated from non-VOC-infected patients. In fact, VH1-58 is the most enriched germline gene in antibodies isolated from this cohort and may play an important role in neutralizing a broad spectrum of variants. As the epitope of VH1-58 antibodies remains a site of vulnerability in all currently circulating VOCs, these findings provide valuable insights for next-generation vaccine design and antibody therapeutics against present and future variants. For example, simultaneous and/or sequential immunization with vaccines based on diverse RBD sequences could be evaluated for superiority in induction of cross-variant immunity including recruitment of highly potent VH1-58 antibodies. Novel vaccine candidates based on the Beta variant have already showed promising cross-variant antibody titers in pre-clinical studies (<xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R30">30</xref>), which led to the subsequent initiation of a phase II/III clinical trial. These clinical trials should be complemented by studies characterizing the immune response against further SARS-CoV-2 variants including the Delta variant, which is currently the globally dominating SARS-CoV-2 VOC.</p>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Materials</label>
<media xlink:href="EMS136060-supplement-Supplementary_Materials.pdf" mimetype="application" mime-subtype="pdf" id="N67021" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S1">
<title>Acknowledgements</title>
<p>We thank all study participants who devoted samples and time to our research, Dr. Kim Stahlberg for patient recruitment, Stefanie Bandura, Matthias Sillmann, Doreen Brandl, Patricia Tscheak, and Sabine Engl for excellent technical assistance, and Dr. Marcel A Müller and Dr. Daniela Niemeyer for support with BSL3 work. We acknowledge BIAFFIN GmbH &amp; Co. KG (Kassel, Germany) for performance of SPR measurements and the Flow &amp; Mass Cytometry Core Facility at Charité-Universitätsmedizin Berlin for support with single-cell sorting. We thank Robyn Stanfield for assistance in data collection, Fangzhu Zhao for assistance in the biolayer interferometry binding assay, and the staff of Advanced Light Source beamline 5.0.1 and Stanford Synchrotron Radiation Laboratory (SSRL) beamline 12-1 for assistance. SARS-CoV-2 RBD variants antigens for sera testing were kindly provided by InVivo BioTech Services GmbH (Hennigsdorf, Germany) to the Seramun Diagnostica GmbH (Heidesee, Germany). S.M.R. and J.K. are participants in the BIH-Charité Junior Clinician Scientist Program and V.M.C is supported by Berlin Institute of Health (BIH) Charité Clinician Scientist program both funded by Charité – Universitätsmedizin Berlin and the Berlin Institute of Health.</p>
<sec id="S2">
<title>Funding</title>
<p>This work was supported by the Bill and Melinda Gates Foundation INV-004923 (I.A.W.), by the Bavarian State Ministry of Science and the Arts; University Hospital; Ludwig-Maximilians-Universität Munich; German Ministry for Education and Research (Proj. Nr.: 01KI20271, M.H.); by the Helmholtz Association (ExNet-0009-Phase2-3, D.S.), and by the Austrian Science Fund (FWF J4157-B30, M.R.). Parts of the work was funded by the European Union's Horizon 2020 research and innovation program through project RECOVER (GA101003589) to C.D.; the German Ministry of Research through the projects VARIPath (01KI2021) to V.M.C and NaFoUniMedCovid19 - COVIM, FKZ: 01KX2021 to C.D., and V.M.C. This research used resources of the Advanced Light Source, which is a DOE Office of Science User Facility under contract number DE-AC02-05CH11231.Use of the SSRL, SLAC National Accelerator Laboratory, is supported by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Contract No. DE-AC02–76SF00515. The SSRL Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research, and by the National Institutes of Health, National Institute of General Medical Sciences (including P41GM103393).</p>
</sec>
</ack>
<sec id="S3" sec-type="data-availability">
<title>Data and materials availability</title>
<p id="P14">X-ray coordinates and structure factors are deposited at the RCSB Protein Data Bank under accession codes 7S5P, 7S5Q and 7S5R. The amino acid sequences of the antibodies described in this study can be found in <xref ref-type="supplementary-material" rid="SD1">table S3</xref>. All requests for materials including antibodies, viruses, plasmids and proteins generated in this study should be directed to the corresponding authors. Materials will be made available for non-commercial usage.</p>
</sec>
<fn-group>
<fn id="FN3" fn-type="con">
<p id="P15">
<bold>Author contributions:</bold> Conceptualization: S.M.R., M.Y., H.-C.K., V.M.C., H.P., I.A.W., and J.K.; Patient recruitment and sample preparation: S.M.R., M.R., M.A.H., I.K., T.M.E., C.G., A.W., M.H., H.G., G.W., S.H., H.P., and J.K.; Antibody production: S.M.R., S.v.H., E.S.-S., M.R., S.E.B., H.F.R., M.A.H., L.S., D.K., N.v.W., and J.K.; Antibody reactivity testing: H.-C.K.; Serological assays and neutralization testing: V.M.C., M.L.S., T.S., L.M.J., and C.D.; Protein production and crystallography: M.Y., W.Y., Y.H., and H.T.; Software: M.B., J.H., and S.M.R.; Resources: V.M.C., M.H., G.W., D.S., C.D., H.P., and I.A.W.; Writing – Original Draft: S.M.R., M.Y., H.-C.K., H.P., I.A.W., and J.K.; Writing – Review &amp; Editing: all authors; Supervision: S.M.R., M.Y., H.-C.K., V.M.C., H.P., I.A.W., and J.K.</p>
</fn>
<fn id="FN4" fn-type="conflict">
<p id="P16">
<bold>Competing interests:</bold> The German Center for Neurodegenerative Diseases (DZNE) and Charité-Universitätsmedizin Berlin have filed a patent application on antibodies for the treatment of SARS-CoV-2 infection described in an earlier publication, on which S.M.R., H.-C.K., V.M.C., E.S.-S., H.P., and J.K. are named as inventors. V.M.C. is named together with Euroimmun GmbH on a patent application filed recently regarding the diagnostic of SARS-CoV-2 by antibody testing.</p>
</fn>
</fn-group>
<ref-list>
<title>References and Notes</title>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody evasion by the P.1 strain of SARS-CoV-2</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2939</fpage>
<lpage>2954</lpage>
<elocation-id>e9</elocation-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7</article-title>
<source>Nature</source>
<year>2021</year>
<volume>593</volume>
<fpage>130</fpage>
<lpage>135</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2384</fpage>
<lpage>2393</lpage>
<elocation-id>e12</elocation-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination</article-title>
<source>Cell Rep</source>
<year>2021</year>
<volume>36</volume>
<elocation-id>109415</elocation-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Planas</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies</article-title>
<source>Nat Med</source>
<year>2021</year>
<volume>27</volume>
<fpage>917</fpage>
<lpage>924</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2348</fpage>
<lpage>2361</lpage>
<elocation-id>e2346</elocation-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Widera</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Limited neutralization of authentic SARS-CoV-2 variants carrying E484K in vitro</article-title>
<source>J Infect Dis</source>
<year>2021</year>
<elocation-id>jiab355</elocation-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rapp</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class</article-title>
<source>Cell Rep</source>
<year>2021</year>
<volume>35</volume>
<elocation-id>108950</elocation-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants</article-title>
<source>Science</source>
<year>2021</year>
<volume>373</volume>
<fpage>818</fpage>
<lpage>823</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies</article-title>
<source>Nature</source>
<year>2020</year>
<volume>588</volume>
<fpage>682</fpage>
<lpage>687</lpage>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucas</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity in uninfected and previously infected individuals</article-title>
<source>medRxiv</source>
<year>2021</year>
<elocation-id>2021.2007.2014.21260307</elocation-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geers</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees</article-title>
<source>Sci Immunol</source>
<year>2021</year>
<volume>6</volume>
<elocation-id>eabj1750</elocation-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cevik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Grubaugh</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Openshaw</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolfel</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Virological assessment of hospitalized patients with COVID-2019</article-title>
<source>Nature</source>
<volume>581</volume>
<year>2020</year>
<fpage>465</fpage>
<lpage>469</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreye</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis</article-title>
<source>Brain</source>
<volume>139</volume>
<year>2016</year>
<fpage>2641</fpage>
<lpage>2652</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tiller</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning</article-title>
<source>J Immunol Methods</source>
<volume>329</volume>
<year>2008</year>
<fpage>112</fpage>
<lpage>124</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raybould</surname>
<given-names>MIJ</given-names>
</name>
<name>
<surname>Kovaltsuk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Marks</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Deane</surname>
<given-names>CM</given-names>
</name>
</person-group>
<article-title>CoV-AbDab: the coronavirus antibody database</article-title>
<source>Bioinformatics</source>
<year>2021</year>
<volume>37</volume>
<fpage>734</fpage>
<lpage>735</lpage>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreer</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>1663</fpage>
<lpage>1673</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreye</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology in a COVID-19 hamster model</article-title>
<source>Cell</source>
<volume>183</volume>
<year>2020</year>
<fpage>1058</fpage>
<lpage>1069</lpage>
<elocation-id>e19</elocation-id>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbiani</surname>
<given-names>DF</given-names>
</name>
<etal/>
</person-group>
<article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>437</fpage>
<lpage>442</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants</article-title>
<source>Nature</source>
<year>2021</year>
<volume>592</volume>
<fpage>616</fpage>
<lpage>622</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<etal/>
</person-group>
<article-title>Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>828</fpage>
<lpage>842</lpage>
<elocation-id>e16</elocation-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>NC</given-names>
</name>
<etal/>
</person-group>
<article-title>An alternative binding mode of IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain</article-title>
<source>Cell Rep</source>
<year>2020</year>
<volume>33</volume>
<elocation-id>108274</elocation-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural basis of a shared antibody response to SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1119</fpage>
<lpage>1123</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Wilson</surname>
<given-names>IA</given-names>
</name>
</person-group>
<article-title>Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies</article-title>
<source>Biochem Biophys Res Commun</source>
<year>2021</year>
<volume>538</volume>
<fpage>192</fpage>
<lpage>203</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants</article-title>
<source>Science</source>
<year>2021</year>
<volume>373</volume>
<elocation-id>eabh1766</elocation-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>The antigenic anatomy of SARS-CoV-2 receptor binding domain</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<fpage>2183</fpage>
<lpage>2200</lpage>
<elocation-id>e22</elocation-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>
<article-title>Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>950</fpage>
<lpage>957</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spencer</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>
<article-title>The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 Beta (B.1.351) and other variants of concern in preclinical studies</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>21.06.2008.447308</elocation-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ying</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains</article-title>
<source>bioRxiv</source>
<year>2021</year>
<elocation-id>2021.08.025.457693</elocation-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyd</surname>
<given-names>SD</given-names>
</name>
<etal/>
</person-group>
<article-title>Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangements</article-title>
<source>J Immunol</source>
<year>2010</year>
<volume>184</volume>
<fpage>6986</fpage>
<lpage>6992</lpage>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reincke</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Pruss</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kreye</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Brain antibody sequence evaluation (BASE): an easy-to-use software for complete data analysis in single cell immunoglobulin cloning</article-title>
<source>BMC Bioinformatics</source>
<year>2020</year>
<volume>21</volume>
<fpage>446</fpage>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Eils</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Schlesner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brors</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>circlize Implements and enhances circular visualization in R</article-title>
<source>Bioinformatics</source>
<year>2014</year>
<volume>30</volume>
<fpage>2811</fpage>
<lpage>2812</lpage>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hillus</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study</article-title>
<source>Lancet Respir Med</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harvey</surname>
<given-names>WT</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 variants, spike mutations and immune escape</article-title>
<source>Nat Rev Microbiol</source>
<year>2021</year>
<volume>19</volume>
<fpage>409</fpage>
<lpage>424</lpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otto</surname>
<given-names>SP</given-names>
</name>
<etal/>
</person-group>
<article-title>The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic</article-title>
<source>Curr Biol</source>
<year>2021</year>
<volume>31</volume>
<fpage>R918</fpage>
<lpage>R929</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ekiert</surname>
<given-names>DC</given-names>
</name>
<etal/>
</person-group>
<article-title>A highly conserved neutralizing epitope on group 2 influenza A viruses</article-title>
<source>Science</source>
<year>2011</year>
<volume>333</volume>
<fpage>843</fpage>
<lpage>850</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<volume>29</volume>
<fpage>806</fpage>
<lpage>818</lpage>
<elocation-id>e806</elocation-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Otwinowski</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Minor</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>Processing of X-ray diffraction data collected in oscillation mode</article-title>
<source>Methods Enzymol</source>
<year>1997</year>
<volume>276</volume>
<fpage>307</fpage>
<lpage>326</lpage>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCoy</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Phaser crystallographic software</article-title>
<source>J Appl Crystallogr</source>
<year>2007</year>
<volume>40</volume>
<fpage>658</fpage>
<lpage>674</lpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Emsley</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Lohkamp</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Cowtan</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Features and development of Coot</article-title>
<source>Acta Crystallogr D Biol Crystallogr</source>
<year>2010</year>
<volume>66</volume>
<fpage>486</fpage>
<lpage>501</lpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>PD</given-names>
</name>
<etal/>
</person-group>
<article-title>PHENIX: a comprehensive Python-based system for macromolecular structure solution</article-title>
<source>Acta Crystallogr D Biol Crystallogr</source>
<year>2010</year>
<volume>66</volume>
<fpage>213</fpage>
<lpage>221</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krissinel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Henrick</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Inference of macromolecular assemblies from crystalline state</article-title>
<source>J Mol Biol</source>
<year>2007</year>
<volume>372</volume>
<fpage>774</fpage>
<lpage>797</lpage>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>VB</given-names>
</name>
<etal/>
</person-group>
<article-title>MolProbity: all-atom structure validation for macromolecular crystallography</article-title>
<source>Acta Crystallogr D Biol Crystallogr</source>
<year>2010</year>
<volume>66</volume>
<fpage>12</fpage>
<lpage>21</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<boxed-text id="BX1" position="float" orientation="portrait">
<caption>
<title>One sentence summary</title>
</caption>
<p>SARS-CoV-2 Beta variant elicits lineage-specific antibodies and antibodies with neutralizing breadth against wild-type virus and VOCs.</p>
</boxed-text>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<title>Authentic virus neutralization of sera from individuals after infection with SARS-CoV-2 Beta.</title>
<p>
<bold>(A-B)</bold> Neutralizing activity of sera of patients infected with SARS-CoV-2 Beta variant was measured using a plaque-reduction neutralization assay with the indicated authentic virus. Results are given as reduction of plaque number at indicated serum dilutions. Patient SA1 and SA2 are highlighted in red and blue, respectively. Means of duplicate measurements are shown. Values below zero indicate no plaque reduction. <bold>(C)</bold> Change in neutralization activity against SARS-CoV-2 Beta and non-VOC SARS-CoV-2 based on area under the curve (AUC) calculations from authentic virus PRNT curves (shown in <bold>A</bold> and <bold>B</bold>). Mean fold change is indicated above the p value. Statistical analysis was performed using a Wilcoxon matched-pairs signed-rank test with two-tailed p value.</p>
</caption>
<graphic xlink:href="EMS136060-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<title>Germline gene usage and clonotype analysis of Beta-elicited antibodies.</title>
<p>
<bold>(A)</bold> VH gene usage of 289 RBD Beta IgG mAbs from this study (red) is compared to 1037 non-VOC RBD mAbs from 96 previously published studies (blue, Cov-AbDab) (<xref ref-type="bibr" rid="R17">17</xref>). Frequencies of mAbs encoded by each VH gene are shown as bars. Enrichment of indicated VH genes is compared to healthy individuals (<xref ref-type="bibr" rid="R31">31</xref>) with fold-enrichment shown as number next to bars. VH gene frequencies that were not reported in healthy individuals (<xref ref-type="bibr" rid="R31">31</xref>) are shown with asterisk (*). Only VH genes with a frequency of at least 2% in Cov-AbDab are shown and VH genes are ordered by frequency in Cov-AbDab. <bold>(B</bold>) Circos plot shows the relationship between 289 IgG mAbs from this study (Beta) and 1037 previously published human mAbs reactive to RBD (non-VOC) from 96 studies (<xref ref-type="bibr" rid="R17">17</xref>). Interconnecting lines display clonotypes shared between both datasets, as defined by the usage of the same V and J gene on both Ig heavy and light chain. Thin black lines at the outer circle border indicate expanded clonotypes within the respective data set. <bold>(C)</bold> Circos plot displaying the 289 IgG mAbs from this study grouped per patient. Interconnecting colored lines indicate clonotypes found in more than one patient. Small black angles at the outer circle border indicate clonally expanded clones within one patient. <bold>(B-C)</bold> Colored interconnecting lines depict clonotypes found in more than one patient of our cohort.</p>
</caption>
<graphic xlink:href="EMS136060-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<title>Binding, neutralization and structures of Beta-specific antibodies.</title>
<p>
<bold>(A)</bold> Neutralization of indicated Beta-specific mAbs against authentic Beta virus is shown in purple. Binding to single point mutant RBD constructs with the indicated amino-acid residues at positions 417, 484 and 501 is shown in green, normalized to RBD Beta. <bold>(B-G)</bold> Structural comparison of VH3-53 mAbs between Beta-specific CS23 and non-VOC-specific CC12.1 and CC12.3. <bold>(B)</bold> CC12.3 and CS23 adopt the same binding mode. The crystal structure of CC12.3 (pink) in complex with RBD (non-VOC) was superimposed onto CS23 (yellow) in complex with RBD (Beta). Only the variable domains of the antibodies are shown for clarity. A small local conformational difference was observed between CS23-bound Beta-RBD and CC12.3-bound non-VOC-RBD (191 Cα, RMSD = 0.8 Å). <bold>(C-D)</bold> Comparison of the <bold>(C)</bold> CDR H1 (‘NY’ motif) and <bold>(D)</bold> CDR H2 (‘SGGS’ motif) between CS23 and CC12.3. <bold>(E-G)</bold> Structures of CDR H3 of <bold>(E)</bold> CC12.1, <bold>(F)</bold> CC12.3, and <bold>(G)</bold> CS23. A modeled side chain of K417 is shown as transparent pink sticks, which would be unfavorable for binding to CS23, where V<sub>H</sub> M98 occupies this pocket. Structures of CC12.1 (PDB 6XC3, cyan), CC12.3 (PDB 6XC4, pink), and CS23 (this study, yellow) are used throughout this figure, and the RBD is shown in white. Hydrogen bonds, salt bridges or cation-π bonds are represented by black dashed lines.</p>
</caption>
<graphic xlink:href="EMS136060-f003"/>
</fig>
<fig id="F4" position="float">
<label>Fig. 4</label>
<caption>
<title>Characterization of cross-reactive mAbs and crystal structures of CV07-287 and CS44.</title>
<p>
<bold>(A)</bold> Neutralization of cross-reactive antibodies against authentic Beta, Delta and non-VOC virus is shown in purple. Binding to the indicated RBD constructs is shown in green, normalized to RBD Beta. <bold>(B)</bold> Comparison of sequence features from VH1-58 mAbs. <bold>(C)</bold> VH1-58 antibodies target SARS-CoV-2 RBD via the same binding mode. Crystal structures of CV07-287 in complex with non-VOC RBD and CS44 in complex with RBD Beta are shown. COVA1-16 Fab that was used in the crystallization to form the crystal lattice is not shown for clarity. Structures of VH1-58 antibodies from other studies are shown for comparison, including COVOX-253 (PDB 7BEN), S2E12 (PDB 7K45), A23-58.1 (PDB 7LRT), and B1-182.1 (PDB 7MM0). All structures are shown in the same orientation, with the constant domains of the Fab omitted for clarity. The location of the ridge region of the RBD is indicated in the first panel. of the Fab omitted for clarity. The location of the ridge region of the RBD is indicated in the first panel. <bold>(D)</bold> Sequence logo of CDR H3 of VH1-58/VK3-20 antibodies. CDR H3 sequences of VH1-58/VK3-20 antibodies from COVID-19 patients (<xref ref-type="bibr" rid="R17">17</xref>) were aligned and analyzed with WebLogo. <bold>(E-F)</bold> Mutated residues in VOCs B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 (Delta), and P.1 (Gamma) variants are represented by red spheres. All of these residues are distant from VH1-58 antibodies <bold>(E)</bold> CV07-287 and <bold>(F)</bold> CS44, except for T478. The disulfide bond in each CDR H3 is shown as sticks. <bold>(G-J)</bold> Detailed interactions between the RBD and <bold>(G-H)</bold> CV07-287, and <bold>(I-J)</bold> CS44, respectively. RBDs are shown in white, with heavy and light chains of CV07-287 in orange and yellow, and those of CS44 in cyan and light cyan, respectively. Interactions of CDR H2 are shown in panels <bold>(G)</bold> and <bold>(I)</bold>, and those of CDR H3 are in panels <bold>(H)</bold> and <bold>(J)</bold>. Hydrogen bonds are represented by black dashed lines.</p>
</caption>
<graphic xlink:href="EMS136060-f004"/>
</fig>
</floats-group>
</article>
